Group 1: Company Overview - Beijing Bohui Innovation Biotechnology Group Co., Ltd. operates three blood product production enterprises located in Hebei and Guangdong [1] - The company has established a blood product processing plant in Qujing, Yunnan, with a processing capacity of 1,500 tons [1] - A new blood product production facility is being constructed in Hohhot, Inner Mongolia, to expand plasma resources and market reach [1] Group 2: Production and Capacity - The company currently operates 15 plasma collection stations, with 2 additional stations under construction in Inner Mongolia [2] - The plasma collection volume is expected to maintain a growth trend, supported by the increasing number of operational stations [2] - The company has a certain scale of inventory plasma to ensure supply for the second half of the year [2] Group 3: Financial Performance - The company’s blood product business gross margin has significant room for improvement compared to the industry average due to factors like low collection scale and high costs [3] - The first quarter's revenue growth was driven by strong market demand and improved operational efficiency in plasma stations and factories [3] Group 4: Future Plans and Challenges - The timeline for the completion of the Inner Mongolia factory is uncertain due to regulatory approvals required for production [2] - The company conducts annual impairment tests on goodwill as per accounting standards, which may lead to recognition of impairment losses if recoverable amounts are lower than book values [3]

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | |------------|---------------------------------| | | 特定对象调研 | | 投资者关系 | □媒体采访 | | 活动类别 | □新闻发布会 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名 | | | | 国金证券股份有限公司 | | 称及人员姓 | | | | 农银汇理基金管理有限公司 | 名 时间 2023 年 6 月 26 日 15:00-16:00 地点 公司会议室 上市公司接 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、能简单介绍一下大股东情况吗？ 答：公司大股东是杜江涛先生，持有本公司 39.03%股份。另 外，杜江涛先生也持有另一家上市公司君正集团（股票代码： 601216）31.95%股份。 投资者关系 2、公司血液制品业务主要依靠哪些资源发展？ 活动主要内 答：公司自进入血液制品业务以来，在产品研发、浆站拓展方 容介绍 面进行了持续投入，并获得了一定成效，产 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------|---------------------------------|---------| | | | 2023-01 | | | □特定对象调研 | | | 投资者关系 | □媒体采访 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名 | | | | 称及人员姓 | 线上参与公司 2022 | | 名 时间 2023 年 5 月 10 日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事长 沈治卫先生 上市公司接 独立董事 班均先生 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、请问沈董事长，中科生物生产设备进行升级改造进展如 何？何时能恢复正常生产？ 答：中科生物维修改造正按照计划积极推进中，目前正在按 投资者关系 照监管法规要求进行信息化改造，后续需政府相关部门进行验收， 活动 ...

Financial Performance - The company's revenue for Q1 2023 was ¥252,950,995.14, representing a 44.22% increase compared to ¥175,394,242.89 in the same period last year[5] - Net profit attributable to shareholders was ¥5,174,206.08, a significant turnaround from a loss of ¥13,243,101.60 in Q1 2022, marking a 139.07% increase[5] - Basic earnings per share rose to ¥0.0063 from a loss of ¥0.0162, indicating a 138.89% improvement[5] - Total operating revenue for Q1 2023 was CNY 252,950,995.14, an increase of 44.4% compared to CNY 175,394,242.89 in Q1 2022[28] - Net profit for Q1 2023 reached CNY 9,672,620.16, a significant recovery from a net loss of CNY 26,680,596.65 in Q1 2022[29] - The company reported a gross profit margin of approximately 4.9% for Q1 2023, compared to a negative margin in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 9,156,153.67, compared to a loss of CNY 26,934,387.20 in the same period last year[30] Cash Flow and Financial Position - The net cash flow from operating activities improved to ¥5,173,217.62, compared to a negative cash flow of ¥29,404,292.88 in the previous year, reflecting a 117.59% increase[5] - The company reported a decrease in cash and cash equivalents to ¥93,007,540.49 from ¥113,600,046.91 at the beginning of the year, representing a decline of approximately 18.3%[22] - The company’s cash and cash equivalents were CNY 1,103,368,335.50, down from CNY 1,140,130,256.34 in the previous year[24] - The net cash flow from financing activities was CNY 39,680,216.45, a decrease from CNY 132,357,092.92 in the previous year[34] - The company incurred cash outflows from investing activities totaling CNY 65,391,879.04, compared to CNY 37,529,195.84 in the same period last year[34] - The company received CNY 311,022,700.66 in cash from borrowings, significantly higher than CNY 68,000,000.00 in the previous year[34] - The total cash inflow from financing activities was CNY 693,022,700.66, compared to CNY 237,100,000.00 in the same period last year[34] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,883,039,678.80, a slight decrease of 0.64% from ¥3,908,002,277.01 at the end of the previous year[5] - Total liabilities decreased to CNY 1,550,004,592.03 in Q1 2023 from CNY 1,584,123,343.91 in Q1 2022[25] - The company’s equity attributable to shareholders increased to CNY 1,398,188,443.27 from CNY 1,393,532,991.70 year-over-year[26] Operational Highlights - The company experienced a 40.62% increase in cash received from sales, totaling ¥258,419,243.49, driven by growth in blood product sales[12] - The company reported a 715.48% increase in other income, amounting to ¥1,781,470.44, primarily due to increased government subsidies received[10] - The company’s financial expenses decreased by 50.34% to ¥6,238,699.81, attributed to a reduction in short-term debt[10] - Revenue from sales of goods and services received cash of CNY 258,419,243.49, up from CNY 183,767,004.44 in the prior year[32] Shareholder Information - Major shareholder Du Jiangtao holds 39.03% of the shares, totaling 318,811,388 shares[15] - The company has a total of 20,001,720 shares under lock-up, with 178,500 shares released during the period[18] - The company’s vice president reduced her holdings by 179,000 shares at an average price of ¥6.1128 per share, accounting for 0.0219% of the total share capital[19] Investments and Development - The company’s cash outflow for the purchase of fixed assets increased by 74.43% to ¥65,391,879.04, reflecting ongoing investments in the Yunnan blood product project[12] - The company provided guarantees totaling up to ¥650 million for its subsidiaries, with ¥250 million specifically allocated for financing through a cloud platform[20] - The company’s subsidiary obtained a single plasma collection license from the Yunnan Provincial Health Commission[20] - Research and development expenses for Q1 2023 were CNY 14,197,200.03, slightly up from CNY 13,783,836.86 in Q1 2022[29] Receivables and Inventory - Accounts receivable decreased to ¥65,251,577.57 from ¥75,921,242.82, a reduction of about 13.9%[23] - Inventory slightly decreased to ¥860,199,805.87 from ¥870,516,782.75, indicating a decrease of approximately 1.4%[23] - The company’s total receivables from financing decreased to ¥3,120,031.32 from ¥6,485,146.87, a decline of approximately 51.8%[23] - The company’s prepayments increased to ¥15,106,599.30 from ¥8,255,312.80, reflecting an increase of about 83.3%[23]

Financial Performance - The company reported a total revenue of 816.9 million RMB for the year 2022, with no cash dividends distributed to shareholders[5]. - The company's operating revenue for 2022 was ¥795,932,495.41, an increase of 11.36% compared to ¥714,748,462.45 in 2021[20]. - The net profit attributable to shareholders was -¥78,325,488.76, showing a 75.69% improvement from -¥322,176,629.03 in 2021[20]. - The cash flow from operating activities reached ¥40,718,935.07, a significant increase of 4,486.61% compared to ¥887,777.88 in 2021[20]. - The total assets at the end of 2022 amounted to ¥3,908,002,277.01, reflecting a 5.91% increase from ¥3,690,026,740.04 at the end of 2021[20]. - The net assets attributable to shareholders increased by 42.96% to ¥1,393,532,991.70 from ¥974,752,736.01 in 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.0959, improving by 75.68% from -¥0.3944 in 2021[20]. - The company's revenue after deducting non-recurring items was ¥751,603,420.53, up from ¥682,179,143.93 in 2021[21]. - The company’s non-recurring gains totaled ¥17,248,995.25 in 2022, compared to ¥14,891,931.39 in 2021[27]. - The revenue from the biological products segment was ¥503.41 million, accounting for 63.25% of total revenue, with a year-on-year growth of 31.52%[84]. - The revenue from the testing and inspection segment was ¥248.20 million, which represented a decline of 17.11% year-on-year[84]. - The company achieved a gross margin of 15.67% in the biological products segment, which decreased by 9.42% compared to the previous year[87]. - The total revenue for the company in 2022 was approximately ¥795.93 million, representing an increase of 11.36% compared to ¥714.75 million in 2021[84]. Market Position and Strategy - The company maintains a strong commitment to research and development in microfluidic chip technology and molecular diagnostics[13]. - The company is focused on expanding its product offerings based on its existing technology platform to enhance its market presence[39]. - The company is a leader in the trace element detection market, with a stable user base and established products in hospitals[39]. - The company has established a stable partnership with multiple distributors across the country, enhancing its market position through innovative technology and customer network[54]. - The company aims to enhance its market presence through the development of innovative medical devices and technologies[59]. - The company is focused on expanding its operations in the biopharmaceutical market, with plans for potential mergers and acquisitions to enhance its competitive position[180]. - The company is actively pursuing new strategic investments in the blood products sector to enhance its market position[79]. - The company aims to enhance its blood product business by increasing operational efficiency and expanding its market presence over the next 3-5 years[133]. Product Development and Innovation - The company is committed to continuous innovation in the field of medical diagnostics, with multiple products in the pipeline for the next few years[62]. - The company is developing several new diagnostic products, including a high-risk HPV test kit and a respiratory pathogen test kit, aiming for market competitiveness[97]. - The company has developed a series of diagnostic kits for measuring various elements in human blood, including copper, zinc, calcium, magnesium, and iron, with expected launch dates in July 2024[62]. - The company plans to launch a series of new diagnostic kits, including the Procalcitonin Test Kit and the 25-Hydroxyvitamin D Test Kit, with expected registration dates in March 2025[63]. - The company is expanding its product line with a new C-reactive protein testing kit, expected to launch in March 2025, to assess inflammation levels[62]. - The company is focusing on enhancing its diagnostic capabilities through the introduction of quantum dot fluorescence immunoassay methods for various tests[62]. - The Quantum Dot Fluorescence Immunoassay technology is expected to improve the accuracy and efficiency of diagnostic testing[63]. - The company has developed over 20 patents related to its microfluidic chip molecular diagnostic platform, establishing a competitive edge in the automated molecular diagnostic field[76]. Regulatory Compliance and Governance - The company emphasizes its dedication to compliance with regulatory standards set by the China Securities Regulatory Commission[11]. - The company’s blood product offerings comply with strict regulatory policies, which pose challenges for market entry[47]. - The company has passed certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product management[80]. - The company maintains a strict governance structure, ensuring independence from its controlling shareholder in terms of assets, personnel, finance, and operations[159]. - The company has established an independent financial accounting system and management practices, ensuring compliance with relevant laws and regulations[163]. - The company has a dedicated investor relations management system to foster good interactions with investors and maintain a positive image in the capital market[157]. Human Resources and Management - The total number of employees at the end of the reporting period was 1,773, with 299 in the parent company and 1,474 in major subsidiaries[196]. - The company employed 933 technical personnel, 343 production staff, and 197 sales personnel, indicating a strong focus on technical expertise[196]. - The educational background of employees included 24 with doctoral degrees, 50 with master's degrees, and 556 with bachelor's degrees, reflecting a highly educated workforce[196]. - The company implemented a competitive compensation policy to attract and retain talent, ensuring alignment with market standards[198]. - Employee benefits included annual health check-ups, supplemental medical insurance, and various welfare programs to enhance employee satisfaction and loyalty[198]. - The company has maintained a stable management team with no significant changes in senior management positions[171]. - The financial director, Dong Haifeng, has extensive experience in investment management and financial oversight, contributing to the company's financial health[181]. Challenges and Risks - The company is facing risks related to the slow progress of key projects, particularly the resumption of production at Zhongke Biological and the migration of production qualifications for the Yunnan blood product project, which require government approvals[144]. - Continuous investment in R&D, fixed assets, and market promotion has led to a tight financial situation, necessitating increased fundraising efforts to meet business development needs[145]. - The company has established a comprehensive quality management system to address potential risks related to product safety and regulatory compliance[141]. - The company is committed to ensuring product safety and quality control to mitigate risks associated with blood products[140]. Sales and Marketing - The company’s main business revenue from inspection and testing reached 248.2 million yuan, a year-on-year decrease of 17.11%, with medical testing products generating 140.96 million yuan, down 30.22%[55]. - The sales volume of blood products increased by 45.62% year-on-year, with significant contributions from intravenous immunoglobulin and human albumin[90]. - The company’s strategy includes expanding its market presence through competitive pricing and new sales channels, as evidenced by its procurement successes[68]. - The company achieved a sales volume of 527,958 bottles of intravenous immunoglobulin, marking a 35.51% increase from 389,602 bottles in the previous year[70]. Shareholder and Board Information - The annual shareholders meeting had a participation rate of 42.53%[166]. - The company reported a total of 26,906 shares held by directors and supervisors at the end of the reporting period[169]. - The chairman of the board, Zhai Xiaofeng, resigned on May 31, 2022, due to personal reasons[170]. - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and decision-making processes[152]. - The total remuneration for directors, supervisors, and senior management amounted to 5.5753 million yuan[188].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"博晖创新"或"公司"） 2022年年度报告及其摘要已于2023年4月26日刊登于中国证监会指定信息披露网站。 为便于投资者能够进一步了解公司的生产经营情况，公司将于2022年5月10日（星期 三）15:00 —17:00在价值在线（www.ir-online.cn）举办2022年度业绩说明会。 本次业绩说明会将采用网络远程的方式举行，投资者可登陆价值在线（www.ir- online.cn）参与本次年度业绩说明会。 参加本次年度业绩说明会的人员情况如下：董事长沈治卫先生，独立董事班均 先生，董事、财务总监兼董事会秘书董海锋先生。 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-011 北京博晖创新生物技术集团股份有限公司 关于举行 2022 年度业绩网上说明会的公告 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-011 特此公告。 北京博晖创新生物技术集团股份有限公司 董 事 会 2023 年 4 月 26 日 为充分尊重投 ...

Group 1: Company Strategy and Development - The company will continue to focus on its core business areas (IVD and biological products) and enhance user satisfaction while increasing investment in new product development over the next two to three years [2][3] - The company aims to accelerate research and development in the health sector, particularly in IVD, and expand its product line and application areas in analytical instruments [3][4] - The company has completed strategic layouts in inspection, biological products, and research equipment, and plans to further develop products and integrate business operations in these areas over the next three to five years [3][4] Group 2: Financial Performance and Challenges - The management is committed to improving company performance and addressing the pressure on earnings through diligent management practices [3][4] - The company has faced challenges due to rising raw material prices but plans to mitigate these impacts through production line upgrades and supply chain management [5][6] - The company has experienced continuous losses in recent years but is focused on developing new technologies and products to enhance market share and core competitiveness [5][6] Group 3: Product Development and Market Position - The company has invested significantly in the development of blood products, with two subsidiaries now producing seven types of blood products, covering important varieties in the market [5][6] - A new blood product production base with a capacity of 1,500 tons is under construction, which will significantly enhance production capabilities and technical levels [5][6] - The company is actively exploring international markets for its COVID-19 testing kits, having obtained CE certification for its products [4][5] Group 4: Corporate Governance and Investor Relations - Shareholder stock reductions are based on personal decisions and do not reflect concerns about the company's future [6][7] - The company emphasizes compliance with regulations and has taken steps to educate management on legal responsibilities following incidents of stock reduction by executives [6][7] - The company is open to hosting investor visits to enhance understanding and gather constructive feedback [7][8]

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 175,394,242.89, representing a 10.23% increase compared to CNY 159,118,438.30 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 13,243,101.60, which is a 26.47% increase in loss compared to a loss of CNY 10,471,465.66 in the previous year[4] - The net profit for the current period is a loss of $26,680,596.65, compared to a loss of $21,160,208.78 in the previous period, reflecting a deterioration of approximately 26%[26] - The total comprehensive loss for the current period is $26,934,387.20, compared to a loss of $20,954,032.52 in the previous period, indicating an increase in losses of about 28.5%[26] Cash Flow and Operating Activities - The net cash flow from operating activities was a negative CNY 29,404,292.88, a decline of 138.79% from a negative CNY 12,313,915.41 in the same period last year[4] - The cash flow from operating activities shows a net outflow of $29,404,292.88, worsening from a net outflow of $12,313,915.41 in the previous period[28] - The company reported a cash inflow from financing activities of $132,357,092.92, compared to $127,719,272.37 in the previous period, showing a slight increase of about 3.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,768,492,715.30, an increase of 2.13% from CNY 3,690,026,740.04 at the end of the previous year[5] - The total assets of Beijing Bohui Innovation Biotechnology Group Co., Ltd. as of March 31, 2022, amounted to CNY 3,768,492,715.30, an increase from CNY 3,690,026,740.04 at the beginning of the year[22] - Total liabilities rose to CNY 2,862,682,069.22 from CNY 2,757,281,706.76, an increase of about 3.8%[22] - The company's total equity decreased to CNY 905,810,646.08 from CNY 932,745,033.28, a decline of approximately 2.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,030, with the largest shareholder holding 39.03% of the shares[13] Financial Ratios and Performance Metrics - The weighted average return on net assets was -1.37%, a decrease of 40.88% compared to -0.81% in the previous year[5] - Basic and diluted earnings per share for the current period are both -$0.0162, compared to -$0.0128 in the previous period, reflecting a decline in earnings[26] Expenses - The company reported a 68.18% increase in financial expenses, amounting to an increase of CNY 5,093,400, primarily due to increased interest-bearing liabilities to support project construction[9] - Total operating costs for the current period are $200,887,913.43, up from $177,047,246.72 in the previous period, indicating an increase of about 13.4%[25] - Research and development expenses for the current period are $13,783,836.86, down from $15,815,565.02 in the previous period, indicating a decrease of approximately 12.9%[25] Cash and Equivalents - The company's cash and cash equivalents increased to CNY 103,472,840.41 from CNY 39,394,993.04, representing a growth of approximately 163.5%[19] - Cash and cash equivalents at the end of the period amount to $99,811,835.38, an increase from $73,949,719.56 at the end of the previous period, representing a growth of about 35%[29] Inventory and Receivables - Accounts receivable decreased to CNY 88,325,335.14 from CNY 92,107,187.76, a decline of about 4.2%[19] - Inventory increased slightly to CNY 832,530,828.17 from CNY 820,953,599.87, reflecting a growth of approximately 1.7%[19] Non-Current Assets - The company’s non-current assets totaled CNY 2,610,191,804.91, showing a slight decrease from CNY 2,610,465,600.84[22] Short-Term Borrowings - The company’s short-term borrowings increased to CNY 438,304,359.67 from CNY 434,893,006.77, a rise of approximately 0.9%[22] Audit Status - The company has not undergone an audit for the first quarter report[30]

Financial Performance - The company reported a significant loss during the reporting period, primarily due to the suspension and renovation of its subsidiary, Zhongke Biological, leading to a substantial decline in revenue[5]. - The loss was exacerbated by increased external debt and financial expenses to support the construction of the blood product production base in Qujing, Yunnan[5]. - The company's operating revenue for 2021 was ¥714,748,462.45, a decrease of 3.24% compared to ¥738,717,388.06 in 2020[23]. - The net profit attributable to shareholders was -¥322,176,629.03, representing a significant decline of 4,393.41% from a profit of ¥7,503,976.45 in 2020[23]. - The net cash flow from operating activities was ¥887,777.88, down 98.97% from ¥86,137,577.29 in the previous year[23]. - The total assets at the end of 2021 amounted to ¥3,690,026,740.04, a slight decrease of 0.68% from ¥3,715,242,196.65 at the end of 2020[23]. - The net assets attributable to shareholders decreased by 25.02% to ¥974,752,736.01 from ¥1,299,959,538.30 in 2020[23]. - The company reported a basic and diluted earnings per share of -¥0.3944, a decline of 4,386.96% from ¥0.0092 in 2020[23]. - The company’s revenue from core business after deductions was ¥682,179,143.93, down from ¥723,174,605.61 in 2020[23]. - The company’s quarterly revenue showed a decline in the fourth quarter, with a revenue of ¥182,736,686.27 compared to previous quarters[25]. Research and Development - The company has increased its R&D expenditure, indicating a commitment to innovation despite the financial challenges faced[5]. - R&D expenses surged by 69.13% to ¥81.48 million in 2021, reflecting the company's intensified investment in new product development[89]. - R&D investment amounted to ¥90.91 million in 2021, representing 12.72% of operating revenue, up from 10.31% in 2020[92]. - The number of R&D personnel increased by 26.47% to 129 in 2021, with a notable rise in the number of PhD holders from 7 to 15[91]. - The company is developing a fully automated real-time fluorescence nucleic acid detection system, which is expected to enhance market competitiveness upon product registration[90]. - The company aims to achieve product registration for various new products, which will enhance its competitive position in the industry and improve economic benefits[90]. Market and Industry Outlook - The company operates in the in-vitro diagnostics (IVD) sector, which is projected to grow from a market size of $67.11 billion in 2019 to $91.09 billion by 2027, with a CAGR of 4.8%[34]. - The Chinese in vitro diagnostic market is projected to reach ¥288.15 billion by 2030, becoming the largest consumer of in vitro diagnostic products globally[35]. - The blood products industry in China has 28 licensed manufacturers, with a total plasma collection of approximately 9,400 tons in 2021, reflecting a 13% increase from 2020[45]. - The demand for blood products in China exceeds 14,000 tons, indicating a significant supply-demand gap in the market[43]. - The company is focused on expanding its product line with various calibration solutions for blood and serum testing, set for registration renewal in January 2026[55]. Product Development and Sales - The company is set to launch a series of new diagnostic kits, including a combined test kit for rotavirus and enteric adenovirus, expected to be available by January 2024[54]. - A new atomic absorption spectrometer will be introduced in February 2023, designed for measuring lead and cadmium levels in human blood[54]. - The company plans to release multiple atomic absorption spectrometers by April 2024, which will measure various elements including copper, zinc, calcium, magnesium, and iron in human blood[54]. - The company’s blood products are primarily sourced from its plasma collection stations, which are regulated and licensed by provincial health authorities[61]. - The company’s biological products are subject to batch release management, ensuring quality control before market entry[61]. Operational Challenges and Risks - The management has indicated that the current losses are not sustainable and that there are no significant risks to the company's ongoing operations[5]. - Future plans and forward-looking statements in the report carry uncertainties and do not constitute a substantive commitment to investors[5]. - The company is actively addressing potential operational risks and has outlined corresponding measures in the management discussion section of the report[5]. - The company faces operational risks due to the recurring impacts of the COVID-19 pandemic on supply chains and sales[130]. Governance and Management - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and fulfill their duties according to regulations[146]. - The company has a total of 3 supervisors in the supervisory board, ensuring compliance and legality in the performance of duties by directors and senior management[147]. - The company maintains independence in personnel, assets, finance, institutions, and business from the controlling shareholder, ensuring autonomous operation[153]. - The company has established a good interactive relationship with investors, adhering to investor relations management regulations[151]. - The company has a structured decision-making process for determining the remuneration of directors and senior management, involving the nomination and compensation committee[177]. Future Outlook - The company has provided a positive outlook for 2022, projecting a revenue growth of 10% to 1.32 billion RMB[56]. - The company aims to enhance its international presence, with plans to enter two new overseas markets by the end of 2022[56]. - The company has set a future outlook with a revenue target of 1.5 billion yuan for the next fiscal year, indicating a projected growth rate of 25%[171]. - The company plans to enhance its digital marketing strategy, allocating an additional 30 million yuan to increase brand awareness and customer engagement[171].

Financial Performance - The company's operating revenue for 2020 was ¥738,717,388.06, representing a 17.57% increase compared to ¥628,340,031.11 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥7,503,976.45, a significant increase of 195.11% from ¥2,542,755.03 in 2019[18]. - The net cash flow from operating activities improved to ¥86,137,577.29, a 339.09% increase from -¥36,027,044.31 in 2019[18]. - The total assets at the end of 2020 reached ¥3,715,242,196.65, marking a 37.88% increase from ¥2,694,604,343.18 at the end of 2019[18]. - The net assets attributable to shareholders increased by 26.04% to ¥1,299,959,538.30 from ¥1,031,395,597.18 in 2019[18]. - The basic earnings per share for 2020 was ¥0.0092, up 196.77% from ¥0.0031 in 2019[18]. - The weighted average return on net assets was 0.72% for 2020, an increase from 0.22% in 2019[18]. - The company reported a net profit excluding non-recurring gains and losses of ¥3,859,539.32, compared to a loss of -¥11,324,129.26 in 2019, reflecting a 134.08% improvement[18]. - The company achieved a total revenue of CNY 738.72 million in 2020, representing a year-on-year growth of 17.57%[67]. - Net profit attributable to shareholders reached CNY 7.50 million, a significant increase of 195.11% compared to the previous year[59]. Revenue and Sales - The company's operating revenue for 2020 was CNY 139.51 million, a decrease from CNY 227.96 million in 2019, representing a decline of approximately 38.8%[21]. - The net profit attributable to shareholders was a loss of CNY 13.45 million in 2020, compared to a profit of CNY 21.65 million in 2019, indicating a significant downturn[21]. - The in vitro diagnostic business saw a revenue decline of 8.77%, totaling CNY 282.09 million, with reagent sales down by 12.26%[67]. - The biopharmaceutical business reported a revenue of CNY 441.09 million, marking a 43.98% increase, driven by the consolidation of Zhongke Biology and increased vaccine sales[61]. - The company’s blood product sales model includes both distribution and direct sales, targeting hospitals and pharmaceutical distribution enterprises[34]. - The company’s human rabies vaccine is sold directly to disease prevention and control centers nationwide[34]. - The company reported a gross margin of 39.19% for its biopharmaceutical business, an increase of 10.08% year-on-year[70]. Market and Industry Insights - The global in vitro diagnostics (IVD) market was valued at $64 billion in 2019, with a year-on-year growth of 5%[38]. - The Chinese IVD market exceeded RMB 115 billion (over $17 billion) in 2019, growing approximately 15% year-on-year[39]. - The domestic market for molecular diagnostics is one of the fastest-growing segments, accounting for about 20% of the overall IVD market[40]. - The market share of domestic products in the immunology sector is approximately 25%-30%, while biochemical diagnostics exceed 50%[41]. - The blood products industry is experiencing consolidation, with the top five companies holding 80%-85% of the market share globally[45]. - The domestic IVD industry is characterized by a low concentration, with over 600 companies, and the top 20 companies holding only about 30% market share[42]. - The blood products industry in China has high barriers to entry and strict regulations, with significant oversight on plasma collection and product quality[46]. - The domestic market for blood products has substantial growth potential, with the average consumption of immunoglobulin and coagulation factor products in developed countries far exceeding that of China[47]. Research and Development - The company has developed over 20 patents related to its unique microfluidic nucleic acid chip technology, which is a key driver for its HPV testing products[29]. - The company is actively involved in the research and development of vaccines, including human rabies vaccines, expanding its product offerings in the biological products sector[33]. - The company has initiated the development of a new qPCR platform that enhances detection sensitivity and reduces testing time[82]. - The company has completed the prototype manufacturing of a new atomic fluorescence spectrometer, meeting all acceptance criteria[84]. - The company is expanding its product line with new nucleic acid testing kits, including those for COVID-19 and respiratory pathogens, expected to launch in the next two to three years[85]. - The company has invested approximately 36.18 million yuan in the research and development of blood products during the reporting period[86]. - The company aims to enhance the comprehensive utilization of plasma resources to improve product competitiveness[86]. - The R&D investment as a percentage of operating revenue for the past three years indicates a consistent commitment to innovation and product development[87]. - The company reported a significant increase in R&D spending compared to previous years, with a total of ¥76,140,363.67 in 2020[88]. Cash Flow and Financing - The net cash flow from operating activities increased by 339.09% to ¥86,137,577.29 compared to a net outflow of ¥36,027,044.31 in the previous year[94]. - Total cash inflow from operating activities was ¥788,361,005.62, reflecting a year-on-year increase of 13.37%[94]. - Cash inflow from financing activities rose by 192.75% to ¥2,953,185,035.69, primarily due to a prepayment of ¥1.122 billion from a development company[95]. - The net cash flow from financing activities also increased by 207.00% to ¥288,773,772.76[94]. - Investment activities saw a significant cash inflow increase of 37,043.93% to ¥769,510,828.12, attributed to cash recovered from short-term financial management[95]. - The company reported a net increase in cash and cash equivalents of ¥13,176,556.93, a turnaround from a decrease of ¥72,502,275.21 in the previous year, marking an increase of 118.17%[94]. Corporate Governance and Compliance - The company guarantees that all information provided during the transaction process is true, accurate, and complete, with no false records or misleading statements[144]. - The company has fulfilled its legal disclosure and reporting obligations, with no undisclosed contracts, agreements, arrangements, or other matters[145]. - The company has not been subject to any major administrative penalties or criminal sanctions in the last thirty-six months[146]. - The company has committed to providing true, accurate, and complete original written materials to all intermediary institutions involved in the transaction[145]. - The company has not participated in any major asset restructuring that is prohibited by regulations in the last thirty-six months[145]. - The company has undertaken to bear all legal responsibilities for any economic losses or claims arising from violations of the commitments made[146]. Future Outlook and Strategic Plans - The company provided a future outlook, projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[147]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[147]. - The company aims to enhance its core competitiveness through increased R&D investment in its testing and detection business[143]. - The company plans to continue increasing its market development efforts alongside R&D for new products[140]. - The company aims to implement a new customer engagement strategy, which is projected to improve customer retention rates by 30%[147]. Asset Management and Investments - The company has entrusted RMB 752.5 million in bank wealth management products, with no overdue amounts reported[189]. - The company plans to use up to RMB 580 million of idle funds for cash management through bank wealth management products[196]. - The company approved a total credit limit of up to RMB 580 million for comprehensive financing from banks and financial institutions[197]. - The company signed a comprehensive credit contract with Beijing Bank for a maximum credit limit of RMB 30 million[198]. Rental Income and Property Management - The company reported rental income of 2.047 million yuan from properties located in Beijing during the reporting period[178]. - The company generated rental income of 7.1275 million yuan from temporarily idle properties in Beijing during the reporting period[178]. - The total rental income from the properties contributed over 10% to the company's total profit for the reporting period[178]. - The company has a lease agreement with Zhongguancun Life Science Park Development Co., Ltd. for office space, generating a rental income of 3.1442 million yuan[178].